Note 6 - RELATED PARTY TRANSACTIONS (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2018 |
Dec. 31, 2017 |
|
Chief Executive Officer [Member] | ||
Note 6 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||
Debt Instrument, Face Amount | $ 50,000 | |
Due to Related Parties | 50,000 | $ 34,252 |
Research and Development Expense | 59,788 | 62,700 |
Professional Fees | 83,377 | 0 |
Board of Directors Chairman [Member] | ||
Note 6 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||
Selling and Marketing Expense | 15,000 | 38,347 |
Board of Directors Chairman [Member] | Payment for Warehouse Space [Member] | ||
Note 6 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||
Related Party Transaction, Expenses from Transactions with Related Party | 10,626 | $ 15,939 |
Board of Directors Chairman [Member] | Payment for Shared Office Space [Member] | ||
Note 6 - RELATED PARTY TRANSACTIONS (Details) [Line Items] | ||
Related Party Transaction, Expenses from Transactions with Related Party | $ 6,202 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|